Article
The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapies.
Clinical and experimental rheumatology - 1 Jan 2000
Sarsour Khaled, Greenberg Jeffrey, Johnston Joseph A, Nelson David R, O'Brien Lee A, Oddoux Carole, Ostrer Harry, Pearlman Alex, Reed George
Abstract excerpt
OBJECTIVES: There is an association between the FcGRIIIa polymorphism and the development of rheumatoid arthritis (RA). Studies in non-Hodgkin lymphoma demonstrated a relationship between the FcGRIIIa polymorphism and response to anti-CD20 therapies. However, there are currently no published studies evaluating the relationship between this polymorphism and therapeutic response to treatment with anti-CD20 agents...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.